VitaFlow LIBERTY Europe

This is a prospective, single-arm, multi-center, observational, post-market registry to document the clinical safety and performance of MicroPort CardioFlow VitaFlow Liberty™ Transcatheter Aortic Valve System in the routine practice for the treatment of severe aortic valve stenosis. The primary endpoint is the composite rate of all-cause mortality and stroke with disability at 12 months. Patients will receive transcatheter aortic valve replacement and examinations at the screening, procedure, discharge, and follow-up per local standard of care.

NCT Number	NCT06535659
Lead Sponsor	Shanghai MicroPort CardioFlow Medtech Co., Ltd.
Conditions	Aortic Valve Stenosis
Enrollment	122 participants
Start Date	2025-05-06
Primary Completion	2027-06-06 (estimated)
Study Completion	2032-06 (estimated)
Updated on ClinicalTrials.gov	2025-12-29